Drugs and vaccines for COVID-19: List of authorized clinical trials

On this page

The tables below list the COVID-19-related clinical trials which have been authorized by Health Canada through the Food and Drug Regulations or the Interim order for clinical trials for medical devices and drugs related to COVID-19.

This listing represents the initial authorization of the trial, but does not necessarily indicate that the trial is currently active. Status of the trial should be confirmed with the authorization holder.

Health Canada continues to discuss potential clinical trials with a number of sponsors. We will update the lists as new trials related to drugs or vaccines for COVID-19 are authorized.

List of COVID-19 vaccine trials

Table 1. List of COVID-19 vaccines currently in clinical trials authorized by Health Canada
Trial name /Protocol #/control # Title Interventions Authorization holder Authorization date Clinicaltrials.gov link
Ad5-nCoV-2020003
(Control # 239283)
A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults from 18 to <85 years of age in Canada Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5) (Ad5-nCoV) CanSino Biologics Inc. 2020-05-15 NCT04398147
COBRA
(Control # 238868)
A Randomized, Double-blind, Placebo-Controlled Phase 3 Study: Efficacy and Safety of Recombinant BCG VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 Severity Recombinant
Mycobacterium bovis
BCGΔureC::hly
Princess Margaret Cancer Centre 2020-05-08 NCT04439045
COVAC-001
(Control # 247198)
Authorized under the Clinical Trials Interim Order
A Randomized, Observer-Blind, Dose-Escalation Phase I/II Clinical Trial of COVAC Vaccines in Healthy Adults COVAC-2 (nCoV19 S1) VIDO-InterVac, University of Saskatchewan 2020-12-22 NCT04702178
CP-PRO-CoVLP-019
(Control # 240922)
A Randomized, Partially-Blinded, dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18-55 Years of Age Coronavirus-like Particle (CoVLP) COVID-19 Vaccine Medicago Inc. 2020-07-09 NCT04450004
CP-PRO-CoVLP-021
(Control # 245149)
Authorized under the Clinical Trials Interim Order
A Randomized, Observer-Blind, Placebo-Controlled Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age Coronavirus-like Particle (CoVLP) COVID-19 Vaccine Medicago Inc. 2020-11-09 NCT04636697
IC.8
(Control # 240586) Authorized under the Clinical Trials Interim Order
COV-IMMUNO - A Randomized, Phase III Trial of Immunization with IMM-101 versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure IMM-101 Canadian Cancer Trials Group, Cancer Research Institute, Queen's University 2020-06-24 NCT04442048
PRO-CL-001
(Control # 246974)
Authorized under the Clinical Trials Interim Order
A Phase Ia/Ib, First-in-Human, Observer-Blinded, Randomized, Placebo Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64 and ≥ 65 PTX-COVID19-B Providence Therapeutics Holdings Inc. 2020-12-22 N/A
VAC31518COV2001
(Control # 246908)
Authorized under the Clinical Trials Interim Order
A Randomized, Double-blind, Placebo-Controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older and to Evaluate 2 Dose Levels of Ad26.COV2.S in Healthy Adolescents Aged 12 to 17 Years Inclusive Ad26.COV2.S (JNJ-78436735) Janssen Inc. 2020-12-14 NCT04535453
VBI-2902a-CT01
(Control # 246985)
Authorized under the Clinical Trials Interim Order
A Phase 1/2, Randomized, Observer-Blind, Dose-Escalation, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidate (VBI-2902a) in Healthy Adults  VBI-2902a VBI Vaccines Inc. 2020-12-18 N/A

List of COVID-19 treatment trials

Table 2. List of COVID-19 treatments currently in clinical trials authorized by Health Canada
Trial name /Protocol #/control # Title Interventions Authorization holder Authorization date Clinicaltrials.gov link
COVID-NORS-01
(Control # 247971)
The Efficacy of Topical Nitric Oxide Releasing Solutions (NORS) in the Management of Coronavirus Disease 2019 (COVID-19) Nitric Oxide St. Paul's Hospital Vancouver 2021-01-15 N/A
JF-12-2020
(Control # 247938)
Interferon Lambda Therapy for Symptomatic SARS-CoV-2 Early in Infection (ODYSSEY): A phase III randomized, double-blind, placebo-controlled, multicenter, trial to evaluate the effect of peginterferon lambda for the treatment of COVID-19 Peginterferon Lambda-1A Dr. Jordan Feld, University Health Network, Toronto General Hospital 2021-01-13 N/A
SAMI-05-1-01
(Control # 247617)
A Randomized, Open-Label, Controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 in Hospitalized Subjects with Moderate Severity COVID-19 S-1226 (Carbon-Dioxide Perflubron) Solaeromed Inc. 2020-12-31 N/A
REDA-10122
(Control #248696)
Authorized under the Clinical Trials Interim Order
Annexin A5 in Patients with Severe COVID-19 Disease SY-005 (Recombinant Human Annexin A5) Lawson Health Research Institute 2021-02-05 N/A
115769
(Control # 238857)
Safety and Efficacy of Post-Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the prevention of Corona Virus Infectious Disease-19 (COVID-19) in high-risk patients/residents in Institutions Hydroxychloroquine St. Joseph's Health Care Parkwood site 2020-05-09 NCT04371523
20-5449
(Control # 239579)
Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted with COVID-19 Nitric oxide University Health Network 2020-06-25 NCT04383002
2021-6954
(Control # 244461)
Authorized under the Clinical Trials Interim Order
Treatment of Respiratory Complications Associated with COVID-19 Infection Using Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans): a Randomized Phase II Controlled Clinical Trial ProTrans (Wharton's Jelly derived Umbilical Cord Mesenchymal Stromal Cells (UCMSC) Research Institute of the McGill University Health Centre 2020-10-16 N/A
2021-7362
(Control # 246471)
Fluvoxamine for Early Treatment of COVID-19: A Fully Remote, Randomized Placebo Controlled Trial (STOP COVID 2 Canada) Fluvoxamine Research Institute of the McGill University Health Centre 2020-11-30 NCT04668950
2149
(Control # 240138)
Authorized under the Clinical Trials Interim Order
Sedating with Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters and Survival; Multicentre Open-Label, Pragmatic, Randomised Controlled Trial and a Parallel Prospective (Non-Randomised) Cohort Study Isoflurane, sevoflurane Sunnybrook Research Institute 2020-06-10 NCT04415060
776228483 PROACTIVE
(Control # 240296)
Propranolol as an Anxiolytic to Reduce the Use of Sedatives for Critically Ill Adults Receiving Mechanical Ventilation: an Open-Label Randomized Controlled Trial. (PROACTIVE) Propranolol Ottawa Hospital Research Institute 2020-06-10 NCT04467086
AB002
(Control # 238815)
Multicentre, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of LSALT PEPTIDE as Prevention of Acute Respiratory Distress Syndrome (ARDS) in Patients Infected with SARS-COV-2 (COVID-19) LSALT Peptide Arch Biopartners Inc. 2020-05-07 NCT04402957
AGN120-3
(Control # 238605)
A Randomized Open Label Phase 2/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients. NP-120 (fenprodil) Algernon Pharmaceuticals 2020-04-29 NCT04382924
AP-RECAP-AKI-03-01
(Control # 243263)
A Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel-Group, Multi-Center Phase 3 Pivotal Trial to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients with Sepsis Associated Acute Kidney Injury Recombinant human alkaline phosphatase AM-PHARM A B.V. 2020-09-11 NCT04411472
ARBS CORONA II
(Control # 243532)
Authorized under the Clinical Trials Interim Order
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There A Protective Effect of Losartan on Outcomes of Coronavirus Infection? Losartan Providence Health Care Saint Paul's Hospital 2020-09-28 NCT04606563
ATI0320
(Control # 244962)
Favipiravir for Post Exposure Prophylaxis in SARS-COV2-exposed Vulnerable Individuals (PEPCO) Double-blinded, Placebo-Controlled, Randomized, Multinational, Phase-3 clinical Trial to Evaluate the Efficacy of Favipiravir in Preventing the Development of COVID-19 When Given to Asymptomatic SARS-CoV2-Negative Individuals Who Had Direct Exposure to a SARS-CoV2 Infected Person. Favipiravir Appili Therapeutics Inc. 2020-11-02 N/A
BAI_COV19_01
(Control # 239071)
Inhaled NO For The Treatment of COVID-19 Caused by SARS-CoV-2 Nitric oxide Beyond Air. Inc. 2020-05-19 NCT04456088 
BHC-RIB 5401-HC
(Control # 238007)
An Open Label Study to Evaluate the Safety and Efficacy of Virazole® (ribavirin for nhalation solution, USP) in Hospitalized Adult Participants with Respiratory Distress Due to COVID-19 Virazole® (ribavirin) Valeant Canada LP/Valeant Canada S.E.C. 2020-04-08 NCT04356677
CATCO
2114
(Control # 237108)
The Canadian arm of the WHO SOLIDARITY Trial.
A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients.
Remdesivir, interferon beta-1a Sunnybrook Research Institute 2020-03-18 NCT04330690
CIAO_COVID20
(Control # 246983)
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) – An Adaptive Phase II Randomized-Controlled Clinical Trial Xolair (omalizumab) The Research Institute of the McGill University Health Centre 2020-12-21 N/A
CINC424J12301 RUXCOVID
(Control # 240395)
Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Ruxolitinib in Patients with COVID-19 Associated Cytokine Storm (RUXCOVID) Jakavi (ruxolitinib) Novartis Pharmaceuticals Canada Inc. 2020-06-16 NCT04362137
CIRCA-19
(Control # 238608)
Cellular Immunotherapy for COVID-19 acute Respiratory Distress Syndrome (ARDS) (1) Allogeneic Bone Marrow Mesenchymal Stromal Cells (BM-MSCs) / (2) Allogeneic Umbilical Cord Mesenchymal Stromal Cells (UC-MSC) Ottawa Hospital Research Institute 2020-05-15 NCT04400032
COLCORONA
MHIPS-2020-001
(Control # 237317)
Colchicine coronavirus SARS-COV2 trial (COLCORONA) Colchicine Montreal Heart Institute 2020-03-20 NCT04322682
CONCOR-Kids
(Control # 238820)
CONCOR-KIDS: A Randomized, Multicentered, Ppen-Label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus-Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized cChildren Apheresis frozen plasma from recovered COVID-19 patients (convalescent plasma) C17 Council 2020-05-04 NCT04377568
CONTROL-COVID-Favipiravir-1
(Control # 239133)
Control of COVID-19 Outbreak in Long Term Care Favipiravir Appili Therapeutics Inc. 2020-05-18 NCT04448119
CORIPREV-1
(Control # 237350)
COVID-19 Ring-Based Prevention Trial with lopinavir/ritonavir (CORIPREV-LR). Lopinavir/ Ritonavir Unity Health Toronto 2020-03-21 NCT04321174
COV-01
(Control # 242568)
Authorized Under the Clinical Trials Interim Order
Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients Taltz (ixekizumab) / Otezla (apremilast) Amgen Canada Inc. 2020-08-20 NCT04590586
COVACTA
(Control #: 237397)
A Randomised, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia. Actemra®/RoActemra®
(tocilizumab)
Hoffmann-La Roche Limited 2020-03-25 NCT04320615
COVID-CTP-01 (Control # 237786) Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating NORS Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers & Individuals at Risk of Infection Nitric oxide Sanotize Research & Development Corp. 2020-04-18 NCT04337918
COVID-CTP-02 (Control #240702) Multi-center, Double-Blinded Placebo-Controlled, Phase II Clinical Efficacy Study Evaluating NORS to Treat and Prevent the Exacerbation of Infection in Individuals with Documented Mild COVID-19 Nitric oxide Sanotize Research & Development Corp. 2020-06-30 NCT04443868
COVID19 PEP RCT - Canada
2020-6549
(Control #237355)
Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial (COVID19 PEP RCT - Canada) Hydroxychloroquine Research Institute of the McGill University Health Centre 2020-03-25 NCT04308668v
CTO-3212
(Control # 244591)
Authorized under the Clinical Trials Interim Order
Evaluation of The Potential Benefit of Reninangiotens in System Inhibitors (RASI, ACEI/ARB) in High-Risk Patients with COVID-19 Cadesartan / valsartan / ramipril / perindopril / irbesartan / losartan / enalapril / captopril Ottawa Heart Institute Research Corporation 2020-10-16 NCT04591210
CTSN-MSC-ARDS001
(Control # 241138)
Mesenchymal Stromal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome Remestemcel-L Mesoblast, Inc. 2020-07-31 NCT04371393
D1690C00081
(Control # 240352)
Authorized under the Clinical Trials Interim Order
An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients with COVID-19 Dapagliflozin Saint Luke's Hospital of Kansas City 2020-07-04 NCT04350593
DAL-401
(Control # 246298)
Authorized under the Clinical Trial Interim Order
A Double-Blind, Placebo-Controlled Phase 2A Proof-of-Concept trial of Dalcetrapid in Patients with Confirmed Mild to Moderate COVID-19 Dalcetrapid DalCor Pharma UK Ltd   2020-11-26 NCT04676867
DISCONNECT-1
(Control # 241689)
Dismantling COVID Induced Neutrophil ExtraCellular Traps (DISCONNECT-1): Phase I pilot study investigating the safety and feasibility of inhaled rhDNase1 and its impact on neutrophil extracellular traps (NETs) in non-ventilated COVID-19 infected patients Pulmozyme (dornase alfa) The Research Institute of the McGill University Health Centre 2020-07-24 NCT04409925
EB05-04-2020
(Control # 239462)
Authorized under the Clinical Trials Interim Order
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + Standard of Care (SOC) Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 Pneumonia EB05 Edesa Biotech Research Incorporated 2020-06-12 NCT04401475
EXTENDED-P2
(Control # 240041)
EXTENDED (Novel O Therapeutic NaN02 for COVID-19 induced ARDS) Phase IIa Trial Perflenapent (NaNO2) Research Institute of the McGill University Health Centre 2020-06-10 N/A
FAST-1
(Control# 244310)
Authorized under the Clinical Trials Interim Order
Nebulized Furosemide For Pulmonary Inflammation in Intubated Patients with COVID-19 - A Phase 2/3 Study Furosemide Kingston Health Science Centre 2020-10-13 NCT04588792
FIRH_XE006
(Control # 245507)
Lung Structure-Function in Survivors of Mild and Severe COVID19 Infection : 129XE MRI and CT For Rapid Evaluations and Next Wave Healthcare Planning Hyperpolarized Xenon-129 St. Joseph's Healthcare Hamilton 2020-11-05 N/A
GRAAL-2020-01
(Control # 238201)
A Randomized, Open-Label Trial of Convalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1) Apheresis frozen plasma from recovered COVID-19 patients (convalescent plasma) Hamilton Health Sciences 2020-04-16 NCT04348656
GS-US-540-5821
(Control # 238163)
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-COV2 (COV) Infection Remdesivir Gilead Sciences Canada Inc. 2020-04-15 NCT04323761
HEROS-1
(Control # 237851)
Protecting Frontline Health Care Workers from COVID-19 with hydroxychloroquine Pre-Exposure Prophylaxis: A randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada Hydroxychloroquine University Health Network 2020-04-03 NCT04374942
HOPE
ABCOV-01
(Control # 237739)
A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of oral hydroxychloroquine for the treatment of SARS-CoV-2 positive patients for the prevention of severe COVID-19 disease (Short title: ALBERTA HOPE COVID-19) Hydroxychloroquine University of Calgary 2020-04-09 NCT04329611
JF-4-2020
(Control # 238558)
Interferon Lambda for Immediate Antiviral therapy at Diagnosis (ILIAD): A phase II randomized, open-label, multicenter, trial to evaluate the effect of peginterferon lambda for the treatment of COVID-19 Peginterferon Lambda-1A University Health Network 2020-04-29 NCT04354259
JH-COR-003
(Control # 246575)

Authorized under the Clinical Trials Interim Order with Terms and Conditions
NOVATION-1: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19 Novaferon (chimeric interferon α) Genova Inc. 2020-12-11 NCT04669015
LAU-20-01
(Control #238614)
A Double-Blind, Randomized, Placebo-Controlled, Pilot Phase II Study of the Efficacy and Safety of Lau-7B in the Treatment of Adult Hospitalized Patients with COVID-19 Disease LAU-7B (fenretinide) Laurent Pharmaceuticals 2020-05-02 NCT04417257
LESSCOVID
(Control #238851)
Exogenous Surfactant Administration for Patients with COVID-19 BLES (bovine lipid extract surfactant suspension) St. Joseph's Health Centre London 2020-05-05 NCT04375735
LOVIT-COVID MP-31-2021-3741
(Control #239705)
Lessening Organ Dysfunction with VITamin C - COVID (LOVITCOVID) Vitamin C Centre de recherche du centre hospitalier universitaire de Sherbrooke 2020-06-05 NCT04401150
Mild-CONTAIN
2021-6638
(Control # 239123)
Mild - CONTAIN CiclesOnide clinical Trial COVID-19 Treatment Ciclesonide Research Institute of the McGill University Health Centre 2020-05-23 N/A
MK-4482-001
(Control # 244315)
Authorized under the Clinical Trials Interim Order
A Phase 2/3 Randomized, Placebo Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19. MK-4482 Merck Canada Inc. 2020-10-19 NCT04575597
MK-4482-002
(Control # 244159)
Authorized under the Clinical Trials Interim Order
A Phase 2/3 Randomized, Placebo Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. MK-4482 Merck Canada Inc. 2020-10-19 NCT04575584
MP-31-2019-2945
(Control # 237164)
Lessening Organ Dysfunction with Vitamin C (LOVIT) Vitamin C
(ascorbic acid)
Centre de recherche du centre hospitalier universitaire de Sherbrooke 2020-03-18 NCT03680274
MP-37-2021-6659
(Control #238811)
A Multi-Centre, Randomized, Blinded, Placebo Controlled Clinical Trial of the Safety and Effectiveness of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Children Hydroxychloroquine Research Institute of the McGill University Health Centre 2020-05-04 N/A
MUHC_CAMOSTAT MESILATE
(Control #240313)
The Impact of the Camostat Mesilate on COVID-19 Infection: A Randomized Controlled Phase II Clinical Trial Camostat McGill University Health Centre 2020-07-02 N/A
NCT04405102
(Control # 241148)
A Randomized trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - a Pilot Trial (COZI) Ozanimod Institut universitaire de cardiologie et de pneumologie de Québec 2020-07-13 NCT04405102
NTM-CTP-01
(Control # 236728)
An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults & Adolescents with Non-Tuberculous Mycobacteria Nitric oxide Dr. Jeremy Road 2020-03-19 NCT03331445
OHRI-HBOT-001
(Control # 242108)
Multicentre Randomized Controlled Trial of Hyperbaric versus Normobaric oxygen therapy for COVID-19 Patients Oxygen Ottawa Hospital Research Institute 2020-07-30 NCT04500626
ONV2020-003
(Control# 243886)
Authorized under the Clinical Trials Interim Order
A Phase I-Ib, Double-blinded, Randomized Repeated Dose Multicenter, Safety and Immunogenicity Study of Nasal Poly-ICLC (Hiltonol) for Prophylaxis of COVID-19 in Healthy Adults Hiltonol (Polyriboinosinic acid-polyribocytidylic acid (Poly-ICLC)) Oncovir, Inc. 2020-09-25 NCT04672291
OZM-113 (Control # 238691) Therapeutic-dose Anti-coagulation for the Treatment of Hospitalized Patients with COVID-19: the antithrombotic therapy to ameliorate complications of COVID01 (ATTACC) trial Innohep (tinzaparin sodium) / Lovenox (enoxaparin sodium) / Fragmin (dalteparin sodium) / heparin sodium University of Manitoba 2020-04-29 NCT04372589
PDC01
(Control #242430)
A Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety & Efficacy of Dapsone on the Treatment of COVID-19 Positive Patients Dapsone Research Institute of the McGill University Health Centre 2020-08-20 N/A
PHRI.ACT.COVID19
(Control # 238157)
Anti-Coronavirus Therapies to Prevent Progression of COVID-19 (ACT), a Randomized Trial Colchicine / acetylsalicylic acid / rivaroxaban Hamilton Health Sciences 2020-04-18 NCT04324463
PREP2020
(Control #238396)
Pre-Exposure Prophylaxis fro SARS-Coronovirus-2: A Pragmatic Randomized Clinical Trial Hydroxychloroquine University of Manitoba 2020-04-21 N/A
PRO00100606
(Control # 240943)
Improving Vitamin D Status in the Management of COVID-19 Vitamin D Governors of the University of Alberta 2020-07-27 NCT04385940
PROTECT
(Control # 243196)
Prevention of COVID-19 with Oral Vitamin D Supplemental Therapy in Essential Healthcare Teams Cholecalciferol Centre Hospitalier Universitaire Sainte-Justine 2020-09-16 NCT04483635
Protocol 214094
(Control # 239770)
A Randomized, Double-blind, Placebo-Controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients with Severe Pulmonary COVID-19 Related Disease GSK3196165 (otilimab) GlaxoSmithKline 2020-05-27 NCT04376684
RAPID COVID COAG
(Control #238510)
Coagulopathy of COVID-19: A pragmatic randomized controlled trial of therapeutic anticoagulation versus standard care as a rapid response to the COVID-19 pandemic (RAPID COVID COAG) Fondaparinux / Innohep / Fragmin / Lovenox / Lovenox HP / Heparin sodium injection / Heparin sodium and 0.9% sodium chloride injection / Heparin sodium in 5% dextrose injection Unity Health Toronto 2020-04-24 NCT04362085
REB20-0713
(Control # 239287)
A Prospective, Observational Study to Assess the Efficacy and Safety of Adjunctive Humanized Monoclonal Interleukin 6 Receptor Antibody Tocilizumab (TCZ) Therapy to Standard of Care for the Reduction of Hyperinflammation related Mortality in SARS-Cov2 Positive Patients Actemra (tocilizumab) University of Calgary 2020-05-22 NCT04423042
REMAP-CAP
X17-0199
(Control # 237719)
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP):
Pandemic appendix to the core protocol
Interferon beta-1a, apo-hydroxyquine heparin sodium, Lovenox, Fragmin, Innohep, apheresis frozen plasma from recovered COVID-19 patients (convalescent plasma), kineret, vitamin C, simvastatin, acetylsalicylic acid, ticagrelor, clopidogrel, prasugrel Unity Health Toronto 2020-04-01 NCT02735707
ROB0050
(Control # 246389)
Lung Structure-Function in survivors of mild and severe COVID-19 Infection: 129XE MRI and CT for rapid evaluation and next-wave Healthcare Hyperpolarized Xenon-129 Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University 2020-11-27 NCT04584671
SAIL-004
(Control # 237708)
Assessment of Investigational Medications adjunct to Clinical Standard of Care for Treatment of Moderate to Severe Coronavirus Disease (COVID-19) Baricitinib Dr. Lisa Barrett 2020-04-14 NCT04321993
SAR153191
(Control # 237332)
An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients with COVID-19 Kevzara® (sarilumab) Sanofi-Aventis Canada Inc. 2020-03-24 NCT04315298
U-DEPLOY
(OZUHN-001/ Sub-protocol # OZUHN-001-2)
(Control # 237848)
Umbrella Trial Defining Coordinated Approach to Pandemic Trials of COVID-19 and Data Harmonization to Accelerate Discovery Ruxolitinib, placenta derived decidual stromal cells (DSC) University Health Network 2020-04-07 NCT04331665
UHNSEMPATICO1
(Control # 244389)
Semaglutide to reduce Myocardial injury in Patients with COVID-19 Ozempic (semaglutide) University Health Network 2020-10-07 NCT04615871
VASCEPA-COVID-19 CARDIOLINK-9
(Control # 239025)
An Investigation on the Effects of Icosapent Ethyl (Vascepa™) on Inflammatory Biomarkers in Individuals with COVID-19 Cardiolink-9 (Vascepa™) (icosapent) Canadian Medical and Surgical Knowledge Translation Research 2020-05-08 NCT04412018
VIR-7831-5001
(Control # 244708)
Authorized under the Clinical Trials Interim Order
A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-Hospitalized Patients VIR-7831 Vir Biotechnology, Inc. 2020-10-13 NCT04545060
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: